Fig. 6From: Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in GermanyEffect of erenumab on migraine-related symptoms after 3 months of treatment – medical chart review. Multiple responses were possible; EM = episodic migraine; CM = chronic migraineBack to article page